Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapport Therapeutics (RAPP) Non-Current Assets (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Non-Current Assets data on record, last reported at $12.9 million in Q1 2026.

  • On a quarterly basis, Non-Current Assets rose 16.39% to $12.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $56.7 million, a 111.11% increase, with the full-year FY2025 number at $13.9 million, up 170.32% from a year prior.
  • Non-Current Assets reached $12.9 million in Q1 2026 per RAPP's latest filing, down from $13.9 million in the prior quarter.
  • Over the last five years, Non-Current Assets for RAPP hit a ceiling of $15.3 million in Q2 2025 and a floor of $4.6 million in Q4 2023.
  • A 4-year average of $9.8 million and a median of $11.1 million in 2025 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: rose 12.74% in 2024, then surged 181.73% in 2025.
  • Tracing RAPP's Non-Current Assets over 4 years: stood at $4.6 million in 2023, then grew by 12.74% to $5.1 million in 2024, then surged by 170.32% to $13.9 million in 2025, then fell by 6.98% to $12.9 million in 2026.
  • Business Quant data shows Non-Current Assets for RAPP at $12.9 million in Q1 2026, $13.9 million in Q4 2025, and $14.7 million in Q3 2025.